Current and future applications of the anti-IgE antibody omalizumab
Cristoforo Incorvaia1, Marina Mauro2, Gian Galeazzo Riario-Sforza1,Franco Frati3, Francesco Tarantini4, Maurizio Caserini41Allergy/Pulmonary rehabilitation, ICP Hospital, Milan, Italy; 2Allergy Unit, Sant’Anna Hospital, Como, Italy; 3University Department of Obstetric, Gynaecologic and...
Enregistré dans:
Auteurs principaux: | Cristoforo Incorvaia, Marina Mauro, Gian Galeazzo Riario-Sforza, Franco Frati, Francesco Tarantini, Maurizio Caserini |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2008
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/b6d7e8c42c774daebd5b7d44aa092c41 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange
par: Luke F. Pennington, et autres
Publié: (2016) -
The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab
par: Pascal Gasser, et autres
Publié: (2020) -
Two decades with omalizumab: what we still have to learn
par: Incorvaia C, et autres
Publié: (2018) -
Development and characterization of a unique anti‐IgE mouse monoclonal antibody cross‐reactive between human and canine IgE
par: Akiko Kumagai, et autres
Publié: (2021) -
Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement
par: J. M. Orengo, et autres
Publié: (2018)